Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 136,100 shares, a growth of 43.9% from the August 31st total of 94,600 shares. Based on an average daily volume of 73,500 shares, the days-to-cover ratio is currently 1.9 days.

Analyst Upgrades and Downgrades

ENLV has been the topic of a number of research reports. EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Enlivex Therapeutics in a research note on Friday.

Institutional Trading of Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,700,571 shares of the company’s stock, valued at approximately $2,415,000. Armistice Capital LLC owned approximately 8.15% of Enlivex Therapeutics at the end of the most recent reporting period. 1.02% of the stock is owned by institutional investors.

Enlivex Therapeutics Price Performance

Shares of Enlivex Therapeutics stock traded up $0.06 on Friday, reaching $1.64. 196,610 shares of the company were exchanged, compared to its average volume of 136,267. The stock’s 50 day moving average price is $1.34 and its 200-day moving average price is $1.77. The company has a market cap of $35.11 million, a P/E ratio of -1.18 and a beta of 1.03. Enlivex Therapeutics has a 1-year low of $1.15 and a 1-year high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. On average, research analysts predict that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.